NCT05129189

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Shanghai Public Health Clinical Center · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In HIV-infected patients, enhanced PD-1 expression of T cells correlates with T cell depletion, as evidenced by reduced virus-specific proliferative capacity and decreased cytokine expression.Targeting PD-L1 drugs to block PD-1/PD-L1 signaling may promote the secretion of antiviral cytokines and achieve HIV clearance.The mechanism of action of ASC22 is to competitively block the binding of PD-1 molecules to PD-L1 through its antigen-binding region with a high affinity for hPD-L1, thereby stimulating an innate or adaptive immune response with sustained T-cell activation.This study was conducted to evaluate whether ASC22 combined with chidamide in HIV-infected patients with antiviral suppression could shrink the viral reservoir.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	ASC22 group	The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.

Timeline

• Start date: 2022-06-29
• Primary completion: 2023-07-30
• Completion: 2023-07-31
• First posted: 2021-11-22
• Last updated: 2022-09-19

Locations

1 site across 1 country: China